control on overheads with its ongoing program of rationalized assets, products and global presence. Employee and SGA costs decreased by 2% and 1% respectively, while R&D; costs increased only by 1% QoQ. Its adoption of new strategy with cost-benefit analysis of each operational activity helps to limit the reduction of adj. EBITDA margin only by 20bps QoQ to 19.2%, despite one-off inventory adjustment, adverse forex (USD/INR), price erosion in core US generis and recalls of Ranitidine. Adjusted with one-off income of...